Earlier this week, JAMA Pediatrics released the findings of a study which suggested that prenatal exposure to antidepressants may increase the risk of autism spectrum disorders (ASDs). Not surprisingly, this has created a considerable amount [...]
When we meet with women to discuss the reproductive safety of antidepressant medications, one of the most challenging and anxiety-provoking aspects of the consultation is the discussion we have regarding the long-term effects of prenatal [...]
Multiple studies support the efficacy of serotonin reuptake inhibitors (SRIs) for the treatment of premenstrual dysphoric disorder (PMDD). Â In the initial studies, treatment was administered daily throughout the entire menstrual cycle. Â Researchers observed that for [...]
Which treatment is best for managing menopausal sleep problems? We tend to think of estrogen replacement therapy as being the best option for all menopausal symptoms; however, there are other options for managing menopausal symptoms, [...]
Recent research has indicated that selective serotonin reuptake inhibitors (SSRIs) may be an effective option for the treatment of vasomotor symptoms associated with menopause. However, it has been documented in some recent observational studies that [...]
 Over the last decade, numerous studies on the reproductive safety of selective serotonin reuptake inhibitors (SSRIs) have been published.  However, these studies, using different methodologies and studying different populations, have often yielded conflicting results. [...]
In 2006, Chambers and colleagues published an article linking selective serotonin reuptake inhibitor (SSRI) antidepressant use during late pregnancy to an increased risk of persistent pulmonary hypertension in the newborn (PPHN). PPHN is a cardiovascular [...]
A recent paper from the European Menopause and Andropause Society (EMAS) reviews non-hormonal therapy options for the treatment of  menopausal vasomotor symptoms. This EMAS position paper provides guidance for treaters managing peri- and postmenopausal women [...]
Anxiety symptoms are relatively common during pregnancy but typically undiagnosed and undertreated. A recent study of 2793 women observed that 9.5% of women meet criteria for generalized anxiety disorder (GAD) at some point during their pregnancy. The highest rates of GAD were observed in the first trimester (7%). Only 2% of women met criteria for GAD in the second trimester, and 3% in the third trimester.
The following post was first published in OB/GYN News.
